U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07192432) titled 'Gene Therapy for HER-Positive Cancer (SENTRY-HER2)' on Sept. 17.
Brief Summary: This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
HER2 Expressing Solid Tumors
Intervention:
GENETIC: Dose Level 1, VNX-202
Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
GENETIC: Dose Level 2, VNX-202
Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.C...